Meta‐analysis of interstitial pneumonia in studies evaluating iodine‐131‐labeled lipiodol for hepatocellular carcinoma using exact likelihood approach

Abstract

The frequency of interstitial pneumonia appears higher and more precise than previously estimated. The risk appears to be related to the number of injections and the dose level per injection. Generalized linear mixed models using the exact binomial within-study distribution initially described to summarize data on diagnostic evaluation could be relevant for drug-related adverse reaction frequency assessment.

Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres

“…Three small randomised controlled trials were carried out for the palliative treatment of HCC with portal vein thrombosis (PVT) and without PVT, and adjuvant treatment after surgery, with respectively 129, 27, and 43 patients. Despite encouraging results, because of the suboptimal properties of 131 I and a more than expected lung toxicity [144], Lipiocis® is not commercially available anymore in Europe. In-house labelled 131 I-Lipiodol is however still under use in some countries, like for instance India [139].…”

Microfluidic Controllable Preparation of Iodine‐131‐Labeled Microspheres for Radioembolization Therapy of Liver Tumors

“…131 I‐labeled Lipiodol (Lipiocis) has also achieved encouraging results in the treatment of inoperable HCC; however, its greater‐than‐expected pulmonary toxicity has made it no longer commercially available in many countries. [ 42 ] There are literature reports about 131 I‐labeled microspheres. The researchers used the electrophilic substitution reaction between tyrosine residues on collagen or gelatin and iodine to bind 131 I to the microspheres, but the glutaraldehyde crosslinker they used has certain toxicity and poor biocompatibility.…”

Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma

“…The risk appears to be related to the number of injections and the dose level per injection. Its frequency has been estimated at 1.6% after one high dose (Z 2 GBq) and at 4.1% after two or more high doses, with a median delay of 30 days between injection and appearance of the first respiratory symptoms and an 80% mortality rate [37,38]. We had no cases of respiratory insufficiency even among patients with multiple injected doses.…”